We aimed to investigate treatment response, survival profiles, safety profiles, and predictive factors of drug-eluting beads-transarterial chemoembolization (DEB-TACE) with CalliSpheres ® Microspheres (CSM) in treating Chinese hepatocellular carcinoma (HCC) patients.
| INTRODUC TI ON
Hepatocellular carcinoma (HCC) is the sixth most common malignant tumor and the third leading cause of cancer-related death worldwide; meanwhile, there are around 466 100 new cases and 422 100 deaths occurring due to HCC in China according to 2015 cancer statistics. 1, 2 Moreover, a substantial percentage of HCC cases are diagnosed at an advanced stage, with portal vein invasion or intrahepatic metastases, with limited time and chance for treatment, and the highly vascular and necrotic tumors in advanced HCC are prone to develop spontaneous rupture with intraperitoneal hemorrhage, which is a fetal complication of HCC with higher incidence in Asian countries than in Western countries and is classified as stage C by the Barcelona Clinic Liver Cancer (BCLC) staging system. [3] [4] [5] [6] Although the managements for HCC patients have been improved such as diagnostic examinations, surgical technologies, and neoadjuvant therapies, the 5-year survival is still less than 20%, which is far from a satisfactory prognosis. [7] [8] [9] [10] [11] Moreover, a large number of HCC patients present with poor liver function and are not suitable for the current curative treatments (liver transplantation, surgical resection, and radiofrequency ablation) for HCC. Thus, it is in urgent need of exploring additional and effective treatment for HCC patients.
Transarterial chemoembolization (TACE), which is a minimally invasive treatment, has been widely applied in HCC patients, especially in patients who were not eligible for surgery. 1, 12 Conventional TACE, which forms of intra-arterial chemotherapy using lipiodol and chemotherapeutic agents, has been utilized in last decade, while it results in severe cytotoxic effect combined with ischemia and is gradually replaced by drug-eluting beads (DEB)-TACE, which is able to better standardize the treatment procedure and improve the delivery capacity of high dose of chemotherapeutic agents. [13] [14] [15] Regarding the beads used in DEB-TACE, several previous studies applying HepaSphere ® , DcBeads ® , and some other beads have been reported. [16] [17] [18] [19] [20] CalliSpheres ® Microspheres (CSM), which is a type of microbeads made of polyvinyl alcohol hydrogel, is the first DEB product developed in China, and it is able to load some positively charged drugs such as adriamycin, pirarubicin, and epirubicin due to its negatively charged functional groups. [21] [22] [23] [24] A previous study investigating the pharmacokinetics of DEB-TACE with CSM in rabbit liver has demonstrated that DEB-TACE with CSM presents well performance in drug loading, drug releasing, and tolerance, whereas DEB-TACE with CSM has just been used for treating HCC patients in clinical practice within the past 2 years, and limited information about the treatment efficacy of DEB-TACE with CSM in HCC patients is reported. 24 Hence, this study was conducted to investigate the treatment response, survival profiles, safety profiles, and predictive factors of DEB-TACE with CSM in treating Chinese HCC patients.
| MATERIAL S AND ME THODS

| Patients
Sixty-six HCC patients who were about to receive DEB-TACE therapy in The First Affiliated Hospital, Zhejiang University, between January 2016 and January 2018 were consecutively enrolled in this prospective cohort study. The inclusion criteria included the follow- 
| DEB-TACE procedures
Before DEB-TACE treatment, dexamethasone was administrated to patients for allergy prevention, and ondansetron hydrochloride injection was given to patients to prevent gastrointestinal reactions. The CSM (Jiangsu Hengrui Medicine Co., Ltd.) with diameters of 100-300 μm were used for embolization in the DEB-TACE procedures, and the CBs were loaded with Epirubicin (Pfizer) (50 mg, 20 mg/mL solution) and mixed with high concentration contrast agent as 1:1 ratio according to the manufacturer's guidelines.
Before initiation of DEB-TACE procedure, triphasic computerized tomography (CT) or magnetic resonance imaging (MRI) scanning was performed to assess the targeted tumor according to the Milan criteria. 25, 26 Drug-eluting beads-transarterial chemoembolization procedures were performed in the digital subtraction angiography (DSA) room. Firstly, tumor supplying vessels were identified by the hepatic angiography using segment or subsegment super selective catheterization, and then, the femoral artery was punctured using 2.4F microcatheters (Merit Maestro, Merit Medical System, Inc) with Seldinger technique; subsequently, the CBs mixed with chemoembolization reagent and contrast agent were injected into the tumor supplying vessel through the microcatheter, and the end point for embolization was stasis in the flow of contrast agent in the arterial feeders to the tumor. After the embolization, the microcatheter was pulled out and the wound was bandaged. As for the patients with massive HCC, DEB-TACE was performed for multiple times. In addition, all patients were admitted for observation for 24 hours with the punctured leg extended for 6-12 hours following the procedure. After embolization, the analgesic treatment was given to patients with the use of morphine 10 mg (IM) and tramadol 50 mg (po). In addition, omeprazole 40 mg (ivgtt) was given for stomach protection, glutathione 2.4 g (ivgtt) was given for liver protection, and indomethacin suppository 50 mg was given as antipyretic treatment. Moreover, the objective response rate (ORR) was defined as CR + PR. 
| Assessment of treatment response
| Assessment of survival
| Assessment of adverse events
All adverse events were recorded in detail during hospitalization, which included pain, nausea, vomiting, fever, and liver function damage, which was defined as liver function indexes elevated after treatment. Furthermore, numeric rating scale (NRS) was used to evaluate pain grade, which was a 10-point numeric scale, with 0 representing "no pain," 1-3 "mild pain," 4-6 "moderate pain," 7-9 "severe pain," and 10 "unbearable pain," and fever was classified as follows: low-grade fever: 37.3-38.0°C; moderate-grade fever: 38.1-39.0°C; high-grade fever: 39.1-41.0°C; ultrahyperpyrexia: >41°C. SPSS 21 .0 statistical software (SPSS Inc) was used for statistical data processing, and GraphPad Prism 6.01 software (GraphPad Software Inc) was used for figures making. Normal distributed continuous variable was presented as mean value ± SD, skewed distributed continuous variable was presented as median (25th-75th quantiles), and categorized variable was presented as count (percentage). Subgroup analysis of CR was conducted using chi-square test, and survival analysis was performed using Kaplan-Meier method and determined by the Log-rank test. Univariate and multivariate logistic regression models were used to determine the factors predicting CR, and the multivariate logistic regression model analysis was performed using Forward Stepwise (Conditional) method. Univariate and multivariate Cox's proportional hazards regression model analyses were performed to evaluate the prognostic factors, and the multivariate Cox's proportional hazards regression model analysis was performed with the use of Forward Stepwise (Conditional LR) method. P value <0.05 was considered significant, and the significant results were shown in boldface.
| Statistical analysis
| RE SULTS
| Baseline characteristics
A total of 66 HCC patients with a mean age of 59.4 ± 9.9 years were enrolled in this study, including 48 males and 18 females ( Table 1 ). There (37.9%), respectively. The median AFP level was 98.8 (9.8-1004.9) μg/L. 
TA B L E 1 Characteristics of HCC patients at baseline
| Treatment response of patients and nodules
There were 66 patients and 162 nodules available for treatment response. Regarding the treatment response assessed by patients, CR, PR, ORR, SD, and PD rates were 37.9%, 43.9%, 81.8%, 10.6%, and 7.6%, respectively ( Figure 1 ). As to the treatment response assessed by nodules, CR, PR, ORR, SD, and PD rates were 42.0%, 41.4%, 83.4%, 11.7%, and 4.9%, respectively.
| Subgroup analysis of CR
All patients were divided into different groups based on baseline characteristics to evaluate the correlation of CR achievement with baseline characteristics in HCC patients treated by DEB-TACE with CSM (Table 2) 
| Analysis of factors affecting CR
Univariate logistic regression analysis disclosed that number of nodules (≥2 vs 1) (P = 0.001), largest nodule size (≥5 cm vs <5 cm) (P = 0.033), BCLC stage (B/C vs A) (P = 0.005), and AFP (≥98.8 μg/L vs <98.8 μg/L) (P = 0.019) predicted worse CR in HCC patients (Table 3 ). Multivariate logistic regression was conducted to further assess independent factors predicting CR, and a number of nodules (≥2 vs 1) was verified to be an independent factor predicting the absence of CR in HCC patients (P = 0.001).
| Survival profiles
Mean PFS and mean OS in HCC patients were 13.7 (95% CI: 
| Subgroup analysis of PFS and OS
To further investigate the correlation between baseline characteristics and survival profiles, all patients were classified into different groups, and we found the largest sample size ≥5 cm (P = 0.026) ( Figure 3E ) was associated with shorter PFS, and number of nodules ≥2 (P = 0.082) ( Figure 3D) and BCLC stage B/C (P = 0.068) ( Figure 3G ) were numerically associated with poor PFS but without statistical analysis, while no correlation of PFS with age (P = 0.662) ( Figure 3A ), gender (P = 0.723) ( Figure 3B ), relapsed or de novo (P = 0.870) ( Figure 3C ), Child-Pugh stage (P = 0.649) ( Figure 3F ), cycles of DEB-TACE (P = 0.177) ( Figure 3H ), or AFP level (P = 0.193) ( Figure 3I ) was found. As to OS, a number of nodules ≥2 (P = 0.026) ( Figure 4D ), largest nodule size ≥5 cm (P = 0.033) ( Figure 4E ), Child-Pugh B (P = 0.045) ( Figure 4F ), and BCLC stage B/C (P = 0.037) ( Figure 4G) were correlated with decreased OS in HCC patients, while cycles of DEB-TACE ≥2 (P = 0.026) ( Figure 4H ) were correlated with prolonged OS.
However, no correlation of OS with age (P = 0.177) ( Figure 4A ), gender (P = 0.202) ( Figure 4B ), relapsed or de novo (P = 0.510) ( Figure 4C ), or AFP level (P = 0.258) ( Figure 4I ) was observed.
| Analysis of factors affecting PFS and OS
Largest nodule size (≥5 cm vs <5 cm) (P = 0.033) predicted poor PFS according to univariate Cox's regression analysis, which was further verified as an independent predictive factor for shorter PFS in multivariate Cox's regression analysis in HCC patients (Table 4 ) (P = 0.040).
As to factors affecting OS, univariate Cox's regression disclosed that largest nodule size (≥5 cm vs <5 cm) (P = 0.045) and Child-Pugh stage (B vs A) (P = 0.030) predicted worse OS, while cycles of DEB-TACE (≥2 vs 1) (P = 0.036) predicted better OS in HCC patients (Table 5 ).
Moreover, multivariate Cox's regression was performed, and Child-Pugh stage (B vs A) (P = 0.011) and BCLC stage (B/C vs A) (P = 0.044) were independent factors predicting unfavorable OS in HCC patients. After being treated by DEB-TACE in liver cancer patients, there are several common AEs reported, including pain, nausea, and fever.
| Adverse events
An interesting study displays that pain, fever, nausea, vomiting, and liver dysfunction occur in 63.3%, 34.7%, 18.4%, 28.6%, and 55.1% liver cancer patients treated by DEB-TACE with CSM. 18 Besides, AEs including pain (96%), vomiting (16%), and fever (77%) are also reported in another study that treats HCC patients by DEB-TACE with CSM. 21 In this present study, the incidences of liver function damage, pain, nausea, vomiting, and fever were 29 (43.9%), 27 (40.9), 22 (33.3%), 13 (19.7%), and 37 (56.1%), respectively. Compared with the previous studies, fewer incidences of pain and fever were observed in our study, which might result from that we performed preventions for pain, allergy, and gastrointestinal reactions before DEB-TACE procedures;
therefore, AEs such as pain and fever might be milder in our study.
There were some limitations in our study: (a) Sample size in our study (N = 66) was relatively small, and thus, the statistical efficacy might be relatively low, while the sample size in our study was already higher than that in previous studies; moreover, considering DEB-TACE with CSM had just been used for treating HCC patients within the past 2 years, and the sample size was limited; (b) the median follow-up duration of 9.2 months (range: 2.1-24.5 months) in our study was relatively short, so long-term efficacy of DEB-TACE with CSM in HCC patients was not investigated; (c) as a prospective study, we did not intervene the treatment and assignment of patients, and thus, some confounding factors might exist in this study, while their influences have been eliminated by our univariate and multivariate analysis.
In conclusion, DEB-TACE with CSM is an effective and tolerated treatment for Chinese HCC patients, and number of nodules ≥2, largest nodule size ≥5 cm, Child-Pugh stage B, and BCLC stage B/C correlates with unfavorable prognosis.
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